Views & Analysis Will UK patients get access to novel drugs? Access to new medicines is not high up the list of priorities for NHS England, but pharma must seize opportunities to promote innovation uptake.
Views & Analysis Novartis: UK market access starting to resemble austerity-hi... The new head of Novartis UK thinks the country has gone backwards in terms of access to medicines.
Views & Analysis Ultra-rare disease drugs: has access in England just got har... Gaining access to ultra-orphan drugs could become much more difficult.
News Digital mental health platform Healios endorsed by NICE Healios endorsed for improving access to CBT for young people with anxiety.
Partner Content Partner Content Orphan medicines, advances, access and affordability LONDON, UNITED KINGDOM, April 19th 2017:
News NHS to axe 18-week ops waiting target Cancer care and mental health to take priority, says health chief.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.